Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Hospitals & Diagnostics
    • Shalby fixes price...

    Shalby fixes price band between Rs 245-248 per share for IPO

    Written by Ruby Khatun Khatun Published On 2017-11-30T10:30:06+05:30  |  Updated On 18 Aug 2021 3:51 PM IST

    Mumbai: Ahmedabad-based multi-specialty hospital chain Shalby said it has fixed the price band between Rs 245 to Rs 248 per equity share for its proposed initial public offer (IPO) to raise about Rs 504 crore.


    The offer comprises a fresh issue of equity shares aggregating up to Rs 480 crore and an offer for sale of up to 10,00,000 equity shares by the selling shareholder.


    Proceeds of the IPO will be utilized towards repayment of borrowings availed by the company besides purchasing medical equipment for existing, recently set-up as well as upcoming hospitals, the company said. The offer will open on December 5 and closes on December 7.


    "We aim to be one of the leading healthcare service providers in India by expanding the network of hospitals owned and operated through greenfield and brownfield projects, strategic acquisitions and operation and management (O&M) arrangements," Shalby chairman and managing Vikram Shah told reporters here.


    Shalby has 11 operational hospitals, having an aggregate bed capacity of 2,012 beds in Ahmedabad, Mumbai, Indore, and Jaipur.


    The company has entered into a revenue-sharing arrangement with the Mumbai-based Asha Parekh Hospital to construct a 175-bed new hospital at a cost of Rs 120 crore.


    It is also establishing two new hospitals at Nasik in Maharashtra and Vadodara in Gujarat with 113 beds and 150 beds respectively.


    As part of expansion plans, the company also plans to expand its hospital network to northern India, eastern India, and northeastern part of the country, Shah said.


    In the recent months, healthcare services firms Alkem Laboratories, Dr. Lal Pathlabs, Narayana Hrudayalaya, Thyrocare and Eris Lifesciences have tapped the primary market through IPO route.

    AhmedabadAlkem LaboratoriesAsha Parekh HospitalDr Lal PathLabsequity sharesEris LifesciencesfixesHealthcarehospitalsinitial public offeringIPOmedical equipmentmulti-specialty hospital chainNarayana Hrudayalayaprice bandRs 245-248 per shareshalbyShalby HospitalsThyrocareVikram Shah
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok